Intra-individual, randomized comparison of the MRI contrast agents Gadovist 1.0 versus Prohance in patients with primary and secondary brain tumors, evaluated in a blinded read.
Phase of Trial: Phase IV
Latest Information Update: 27 Jul 2011
At a glance
- Drugs Gadobutrol (Primary) ; Gadoteridol
- Indications Brain cancer
- Focus Diagnostic use
- 27 Jul 2011 New trial record